These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 16981959)

  • 1. Low HDL-cholesterol: Common and under-treated, but which drug to use?
    Wierzbicki AS
    Int J Clin Pract; 2006 Oct; 60(10):1149-53. PubMed ID: 16981959
    [No Abstract]   [Full Text] [Related]  

  • 2. Bibliography. Current world literature. HDL cholesterol.
    Curr Opin Cardiol; 2005 Jul; 20(4):365-8. PubMed ID: 16124142
    [No Abstract]   [Full Text] [Related]  

  • 3. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Can cardiovascular events be prevented by raising HDL cholesterol?].
    Langslet G; Reikvam A
    Tidsskr Nor Laegeforen; 2008 Jun; 128(13):1519-23. PubMed ID: 18587459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
    Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
    Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations].
    Birjmohun RS; van der Steeg WA; Stroes ES; Kastelein JJ
    Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2245-50. PubMed ID: 17076358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
    Alrasadi K; Awan Z; Alwaili K; Ruel I; Hafiane A; Krimbou L; Genest J
    Am J Cardiol; 2008 Nov; 102(10):1341-7. PubMed ID: 18993152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-density lipoprotein cholesterol: current perspective for clinicians.
    Whayne TF
    Angiology; 2009; 60(5):644-9. PubMed ID: 19240106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of high-risk older persons with lipid-lowering drug therapy.
    Aronow WS
    Am J Ther; 2008; 15(2):102-7. PubMed ID: 18356628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotinic acid in the treatment of hyperlipidaemia.
    Drexel H
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():5-6. PubMed ID: 18001312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diabetic dyslipidemia: which target levels and treatment options exist for diabetics?].
    Broedl UC; Lehrke M; Parhofer KG
    MMW Fortschr Med; 2008 Jun; 150(25):41-3. PubMed ID: 18705054
    [No Abstract]   [Full Text] [Related]  

  • 15. Longitudinal lipid screening and use of lipid-lowering medications in pediatric type 1 diabetes.
    Maahs DM; Wadwa RP; McFann K; Nadeau K; Williams MR; Eckel RH; Klingensmith GJ
    J Pediatr; 2007 Feb; 150(2):146-50, 150.e1-2. PubMed ID: 17236891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On call. In your January 2007 article on cholesterol, you said that no-flush niacin does not lower cholesterol levels. But my problem is low HDL cholesterol. Will no-flush niacin help my HDL even if it won't lower my LDL cholesterol?
    Simon HB
    Harv Mens Health Watch; 2007 Jun; 11(11):7-8. PubMed ID: 17644843
    [No Abstract]   [Full Text] [Related]  

  • 17. [Favorable effects of decreasing lipids in patients with diabetes mellitus].
    Gouni-Berthold I; Krone W
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S252-4. PubMed ID: 17139581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDL-cholesterol modulation and its impact on the management of cardiovascular risk.
    Ferns G; Keti V
    Ann Clin Biochem; 2008 Mar; 45(Pt 2):122-8. PubMed ID: 18325173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hypolipidemic drugs and diabetes mellitus].
    Bláha V; Mistrík E
    Vnitr Lek; 2009 Apr; 55(4):357-62. PubMed ID: 19449750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment of dyslipidemia--what's left in the pipeline?
    Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
    ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.